Stoke Therapeutics Launches Public Offering for Clinical Development

Stoke Therapeutics Inc (STOK) has provided an announcement.

Stoke Therapeutics, Inc. has launched a public offering, selling over 5.5 million shares and issuing pre-funded warrants for about 3.7 million shares, with J.P. Morgan Securities coordinating as the underwriter. The shares are priced at $13.50 each, while the warrants are slightly less. The company anticipates a net gain of around $119.8 million from the sale, before underwriting costs and other expenses. These funds are earmarked for research, clinical development of product candidates like STK-001 and STK-002, and other corporate expenses, with the offering expected to close on April 2, 2024.

For a thorough assessment of STOK stock, go to TipRanks’ Stock Analysis page.